Companies in #Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Found 1 company operating in this sector.
Aligos Therapeutics is a clinical-stage biopharmaceutical company developing novel therapeutics for liver and viral diseases, with a lead focus on chronic hepatitis B. Its pipeline includes pevifoscorvir sodium, a capsid assembly modulator in Phase 2b for chronic HBV; ALG-055009, a THR-beta agonist in Phase 2a for metabolic dysfunction-associated steatohepatitis (MASH) and obesity; and ALG-097558, a ritonavir-free pan-coronavirus protease inhibitor that has completed Phase 1. In Q2 2026 the company reported $27.8 million in revenue, driven by a $25 million China licensing deal, and narrowed its net loss to $1.5 million.